Category: Nihon Kohden
Automated external defibrillator maker Defibtech agrees to be acquired by Japanese medical device company Nihon Kohden.
The venture capital industry backs a push for passage of a bill that would make it easier for small companies to go public; also, VCs shift focus from high-tech med-tech; S&P affirms Boston Scientific's BBB rating; Allezoe CEO gets threats over PR policy; angels in America spent more on device makers last year; Flextronics buys Stellar Microelectronics; Philips Healthcare wins U.S. Army training contract; OTC exchange lists Avita Medical; iCad wins NASDAQ reprieve; Premier issues new GPO deals; plus, a Funding Roundup and analysts' ups and downs.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
GE Healthcare cuts more employees from its South Burlington, Vt., facility in order to "increase competitiveness."
Updated March 7, 2012, at 1:30 p.m. with comments from GE Healthcare.
MASSDEVICE ON CALL — GE Healthcare (NYSE: GE) announced another round of layoffs at its South Burlington, Vt., facility, a move it said is a result of declining demand for health care IT and performance solutions businesses.
The move is the "subsequent action" of layoffs numbering around 50 workers at the same facility last month, GE spokesman Corey Miller told MassDevice.
Edwards Lifesciences says it will re-state its financials for the 1st 3 quarters of 2011; also, worried that Medtronic's going to burn you?; Dehaier wins credit rating upgrade; InfuSystem taps advisor on "strategic alternatives," shares climb; GPOs: Nihon Koden, Freedom Medical ink deals with Premier; Miracor Medical lands $3.5M grant; Intuitive Surgical marks yet another high; CareFusion wins $44.7M infusion pump contract from the U.S. Defense Dept.; plus, a Deals Roundup and analysts' ups and downs.
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, "due to certain technical errors in the balance sheets and cash flow statements for these interim periods."
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.
